Midazolam and sirolimus transport and inhibition across cell monolayers Data shown are the average ± S.D. (n = 3).
Condition | Papp (A→B) × 106 | Papp (B→A) × 106 | Net Flux Ratio (B→A/A→B) | |
---|---|---|---|---|
cm/s | ||||
Midazolam (3 μM) | ||||
MDR1-MDCK cells | 25 ± 4a | 17 ± 1 | 0.7 ± 0.1 | |
MDCK cells | 16 ± 2 | 17 ± 4 | 1.1 ± 0.3 | |
CYP3A4-transfected Caco-2 | 18.7 ± 0.9 | 18.1 ± 0.6 | 0.97 ± 0.06 | |
+ CsA (10 μM) | 21.0 ± 0.7* | 19 ± 1 | 0.88 ± 0.07 | |
+ GG918 (200 nM) | 17 ± 1 | 18 ± 1 | 1.1 ± 0.1 | |
Midazolam (10 μM)b | ||||
CYP3A4-transfected Caco-2 | 16.5 ± 0.8 | 13.3 ± 0.9 | 0.81 ± 0.07 | |
Sirolimus (1 μM) | ||||
MDR1-MDCK cells | 0.043 ± 0.008 | 3.5 ± 0.4 | 81 ± 17 | |
MDCK cells | 0.9 ± 0.4 | 1.4 ± 0.3 | 1.5 ± 0.7 | |
CYP3A4-transfected Caco-2 | 0.29 ± 0.03 | 0.72 ± 0.03 | 2.5 ± 0.3 | |
+ CsA (10 μM) | 1.77 ± 0.06* | 1.50 ± 0.04* | 0.85 ± 0.04* | |
+ GG918 (200 nM) | 0.45 ± 0.02* | 0.36 ± 0.04* | 0.8 ± 0.1* | |
Sirolimus (20 μM) | ||||
CYP3A4-transfected Caco-2 | 1.7 ± 0.1 | 1.20 ± 0.02 | 0.70 ± 0.05 |